Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination

ConditionHpv
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age9-17
SponsorUniversity of Rochester

About this trial

Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, but have not been evaluated for HPV vaccine, which some parents consider controversial. Also, the ways in which organizational readiness for change (resources, motivation, staff attributes, leadership support and culture) moderate the effect of standing orders has not been studied. A physician's recommendation is correlated with HPV vaccine acceptance, and the investigators have developed a successful online, interactive, communication education program that will be adapted to train nurses and staff in addition to physicians. The investigators propose testing standing orders for HPV vaccine in an Accountable Care Organization (ACO) in Western New York, and assessing which provider and practice factors moderate the effect of standing orders. Advantages of this setting include a diverse group of rural, urban and suburban practices, and the ACO provides data infrastructure and analytics that allow practices to evaluate vaccination rates in real time.

Using a 2-arm cluster randomized trial (n=40 practices), the investigators will assess the effectiveness of standing orders (SO) + HPV communication education (intervention arm) relative to HPV communication education alone (control arm) on HPV vaccination for 9-17 year-olds.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

active patient in AHP practice

Disqualifiers

patient belonging to a practice with >80% UTD baseline HPV vaccination rate for ages 13-17

patient belonging to a practice with <20 11-12 year-olds eligible for an HPV dose

Trial design

Design model

Parallel

Treatments tested in this trial

  • Communication

    Behavioral

    Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.

  • Standing Orders

    Behavioral

    Practice personnel (providers and nurses) receive training in the implementation of standing orders for HPV vaccination via an online learning module and meetings with the study team.

Treatment groups

16,000 Participants
are divided into 2 treatment groups
Group A: Communication TrainingActive comparator 1 intervention
Group B: Communication Training + Standing Orders Training/ImplementationExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Patient-Level Captured Opportunities for HPV Vaccination

The percentage of HPV vaccine eligible patients, aged 9-17, with a practice visit during the specified timeframe of interest who receive \>=1 HPV vaccination.

Time frame
12-month intervention period

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Rochester

Lead sponsor

National Institutes of Health (NIH)

Collaborator

National Cancer Institute (NCI)

Collaborator